By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutical Inc.  

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: 609-730-2000 Fax: n/a



Company News
Janssen Pharmaceutical: New Pan-European Survey Reveals That Only 14% Of Healthcare Professionals Feel Sufficiently Equipped To Address Prostate Cancer Patients’ Quality Of Life Issues 9/16/2015 3:31:19 PM
Long-Lasting Flu Vaccine Comes Closer To Reality, The Scripps Research Institute, Janssen Pharmaceutical Reveals 8/26/2015 6:33:16 AM
Janssen Pharmaceutical Ends Partnership With China's Hutchison Medipharma 8/19/2015 11:59:36 AM
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir On AL-335 Pharmacokinetics 8/3/2015 11:32:57 AM
Data At EULAR 2015 Showcase Commitment Of Janssen Pharmaceutical To Advancing Innovative Treatments For Immune And Inflammatory Diseases 6/2/2015 1:23:06 PM
Poseida Therapeutics Expands Into JLABS To Foster Research Collaboration With Janssen Pharmaceutical For Development Of Allogeneic CAR-T Therapies 6/1/2015 10:45:37 AM
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015 9:16:12 AM
Janssen Pharmaceutical Release: U.S. FDA Issues Complete Response Letter To sNDA Seeking To Expand The Label For INVEGA SUSTENNA 5/12/2015 6:27:34 AM
Janssen Pharmaceutical Completes Divestiture Of U.S. License Rights To NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) Extended-Release Tablets And NUCYNTA (tapentadol) Oral Solution To Depomed, Inc. (DEPO) 4/3/2015 6:34:27 AM
Depomed, Inc. (DEPO) Announces Closing Of Acquisition Of U.S. Rights To NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) Extended Release Tablets And NUCYNTA (tapentadol) Oral Solution From Janssen Pharmaceutical For $1.05 Billion 4/2/2015 3:11:25 PM